ARCT Quote, Financials, Valuation and Earnings

Inovio Pharmaceuticals, Inc. has a net margin of -95.02% compared to Arcturus Therapeutics Holdings, Inc.'s net margin of -30140.49%. Arcturus Therapeutics Holdings, Inc.'s return on equity of -27.98% beat Inovio Pharmaceuticals, Inc.'s return on equity of -252.43%.

Arcturus Therapeutics Holdings, Inc. has a consensus price target of $35.25, signalling upside risk potential of 364.43%. On the other hand Inovio Pharmaceuticals, Inc. has an analysts' consensus of $7.63 which suggests that it could grow by 389.32%. Given that Inovio Pharmaceuticals, Inc. has higher upside potential than Arcturus Therapeutics Holdings, Inc., analysts believe Inovio Pharmaceuticals, Inc. is more attractive than Arcturus Therapeutics Holdings, Inc..

Arcturus Therapeutics Holdings, Inc. has a beta of 2.242, which suggesting that the stock is 124.17% more volatile than S&P 500. In comparison Inovio Pharmaceuticals, Inc. has a beta of 1.618, suggesting its more volatile than the S&P 500 by 61.808%.

Arcturus Therapeutics Holdings, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Inovio Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Arcturus Therapeutics Holdings, Inc. pays -- of its earnings as a dividend. Inovio Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.

Arcturus Therapeutics Holdings, Inc. quarterly revenues are $14.2M, which are larger than Inovio Pharmaceuticals, Inc. quarterly revenues of --. Arcturus Therapeutics Holdings, Inc.'s net income of -$13.4M is higher than Inovio Pharmaceuticals, Inc.'s net income of -$45.5M. Notably, Arcturus Therapeutics Holdings, Inc.'s price-to-earnings ratio is 8.50x while Inovio Pharmaceuticals, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Arcturus Therapeutics Holdings, Inc. is 2.42x versus 346.72x for Inovio Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Myomo, Inc. has a net margin of -95.02% compared to Arcturus Therapeutics Holdings, Inc.'s net margin of -36.3%. Arcturus Therapeutics Holdings, Inc.'s return on equity of -27.98% beat Myomo, Inc.'s return on equity of -68.35%.

Arcturus Therapeutics Holdings, Inc. has a consensus price target of $35.25, signalling upside risk potential of 364.43%. On the other hand Myomo, Inc. has an analysts' consensus of $5.00 which suggests that it could grow by 420.83%. Given that Myomo, Inc. has higher upside potential than Arcturus Therapeutics Holdings, Inc., analysts believe Myomo, Inc. is more attractive than Arcturus Therapeutics Holdings, Inc..

Arcturus Therapeutics Holdings, Inc. has a beta of 2.242, which suggesting that the stock is 124.17% more volatile than S&P 500. In comparison Myomo, Inc. has a beta of 1.052, suggesting its more volatile than the S&P 500 by 5.158%.

Arcturus Therapeutics Holdings, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Myomo, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Arcturus Therapeutics Holdings, Inc. pays -- of its earnings as a dividend. Myomo, Inc. pays out -- of its earnings as a dividend.

Arcturus Therapeutics Holdings, Inc. quarterly revenues are $14.2M, which are larger than Myomo, Inc. quarterly revenues of $10.1M. Arcturus Therapeutics Holdings, Inc.'s net income of -$13.4M is lower than Myomo, Inc.'s net income of -$3.7M. Notably, Arcturus Therapeutics Holdings, Inc.'s price-to-earnings ratio is 8.50x while Myomo, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Arcturus Therapeutics Holdings, Inc. is 2.42x versus 0.95x for Myomo, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Novavax, Inc. has a net margin of -95.02% compared to Arcturus Therapeutics Holdings, Inc.'s net margin of -287.29%. Arcturus Therapeutics Holdings, Inc.'s return on equity of -27.98% beat Novavax, Inc.'s return on equity of --.

Arcturus Therapeutics Holdings, Inc. has a consensus price target of $35.25, signalling upside risk potential of 364.43%. On the other hand Novavax, Inc. has an analysts' consensus of $12.89 which suggests that it could grow by 32.19%. Given that Arcturus Therapeutics Holdings, Inc. has higher upside potential than Novavax, Inc., analysts believe Arcturus Therapeutics Holdings, Inc. is more attractive than Novavax, Inc..

Arcturus Therapeutics Holdings, Inc. has a beta of 2.242, which suggesting that the stock is 124.17% more volatile than S&P 500. In comparison Novavax, Inc. has a beta of 2.367, suggesting its more volatile than the S&P 500 by 136.738%.

Arcturus Therapeutics Holdings, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Novavax, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Arcturus Therapeutics Holdings, Inc. pays -- of its earnings as a dividend. Novavax, Inc. pays out -- of its earnings as a dividend.

Arcturus Therapeutics Holdings, Inc. quarterly revenues are $14.2M, which are smaller than Novavax, Inc. quarterly revenues of $70.4M. Arcturus Therapeutics Holdings, Inc.'s net income of -$13.4M is higher than Novavax, Inc.'s net income of -$202.4M. Notably, Arcturus Therapeutics Holdings, Inc.'s price-to-earnings ratio is 8.50x while Novavax, Inc.'s PE ratio is 5.51x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Arcturus Therapeutics Holdings, Inc. is 2.42x versus 1.55x for Novavax, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Sangamo Therapeutics, Inc. has a net margin of -95.02% compared to Arcturus Therapeutics Holdings, Inc.'s net margin of -6012.05%. Arcturus Therapeutics Holdings, Inc.'s return on equity of -27.98% beat Sangamo Therapeutics, Inc.'s return on equity of -587.71%.

Arcturus Therapeutics Holdings, Inc. has a consensus price target of $35.25, signalling upside risk potential of 364.43%. On the other hand Sangamo Therapeutics, Inc. has an analysts' consensus of $3.25 which suggests that it could grow by 715.56%. Given that Sangamo Therapeutics, Inc. has higher upside potential than Arcturus Therapeutics Holdings, Inc., analysts believe Sangamo Therapeutics, Inc. is more attractive than Arcturus Therapeutics Holdings, Inc..

Arcturus Therapeutics Holdings, Inc. has a beta of 2.242, which suggesting that the stock is 124.17% more volatile than S&P 500. In comparison Sangamo Therapeutics, Inc. has a beta of 1.291, suggesting its more volatile than the S&P 500 by 29.114%.

Arcturus Therapeutics Holdings, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Sangamo Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Arcturus Therapeutics Holdings, Inc. pays -- of its earnings as a dividend. Sangamo Therapeutics, Inc. pays out -- of its earnings as a dividend.

Arcturus Therapeutics Holdings, Inc. quarterly revenues are $14.2M, which are larger than Sangamo Therapeutics, Inc. quarterly revenues of $581K. Arcturus Therapeutics Holdings, Inc.'s net income of -$13.4M is higher than Sangamo Therapeutics, Inc.'s net income of -$34.9M. Notably, Arcturus Therapeutics Holdings, Inc.'s price-to-earnings ratio is 8.50x while Sangamo Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Arcturus Therapeutics Holdings, Inc. is 2.42x versus 3.01x for Sangamo Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.